anmelden
SLI
2.086,84
PKT
-14,92
PKT
-0,71
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.02.22 | Novartis Neutral | UBS AG | |
| 03.02.22 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.22 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 03.02.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 03.02.22 | ABB (Asea Brown Boveri) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 03.02.22 | Novartis Sell | Deutsche Bank AG | |
| 03.02.22 | Nestlé Underperform | Jefferies & Company Inc. | |
| 03.02.22 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 03.02.22 | Nestlé Neutral | Credit Suisse Group | |
| 03.02.22 | Nestlé Overweight | JP Morgan Chase & Co. | |
| 03.02.22 | Novartis Neutral | Credit Suisse Group | |
| 03.02.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Roche Buy | Jefferies & Company Inc. | |
| 03.02.22 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.22 | UBS Overweight | JP Morgan Chase & Co. | |
| 02.02.22 | UBS Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.02.22 | Novartis Market-Perform | Bernstein Research | |
| 02.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.02.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.22 | Novartis Underweight | Barclays Capital | |
| 02.02.22 | Zurich Insurance Overweight | Barclays Capital | |
| 02.02.22 | UBS Equal Weight | Barclays Capital | |
| 02.02.22 | Novartis Buy | Jefferies & Company Inc. | |
| 02.02.22 | UBS Outperform | Credit Suisse Group | |
| 02.02.22 | UBS Outperform | RBC Capital Markets | |
| 02.02.22 | UBS Overweight | JP Morgan Chase & Co. | |
| 01.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 01.02.22 | Givaudan Hold | Deutsche Bank AG | |
| 01.02.22 | UBS Outperform | RBC Capital Markets | |
| 01.02.22 | UBS Overweight | JP Morgan Chase & Co. | |
| 01.02.22 | UBS Buy | Jefferies & Company Inc. | |
| 31.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Givaudan Hold | Deutsche Bank AG | |
| 31.01.22 | Swiss Re Hold | Deutsche Bank AG | |
| 31.01.22 | Novartis Underweight | Barclays Capital | |
| 31.01.22 | Roche Overweight | Barclays Capital | |
| 31.01.22 | Givaudan Underweight | Barclays Capital | |
| 31.01.22 | Givaudan Add | Baader Bank | |
| 31.01.22 | Givaudan Underperform | Credit Suisse Group |